The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury

摘要

The invention relates to the use of an NK-1 receptor antagonist, optionally in combination with a magnesium salt, for the treatment and/or prevention of brain, spinal or nerve injury, wherein said NK-1 receptor antagonist is a compound of the general formula
<Chemistry id="chema01" num="0001"><Image id="ia01" he="40" wi="59" file="IMGA0001.TIF" imgContent="chem" imgFormat="TIFF" /></Chemistry>
wherein the meanings of R, R<Sup>1</Sup>, R<Sup>2</Sup>, R<Sup>2'</Sup>, R<Sup>3</Sup>, R<Sup>4</Sup> are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethylbenzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient for the treatment and/or prevention of brain, spinal or nerve injury.